Wu Shao-Xiong, Deng Mei-Ling, Bao Yong, Wang Han-Yu, Gao Yuan-Hong, Li Feng-Yan, Huang Shao-Min
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Ai Zheng. 2006 Jul;25(7):880-4.
BACKGROUND & OBJECTIVE: There are only a few traditional treatment methods for lung metastasis, and the therapeutic effectiveness is not satisfactory. X-ray stereotactic radiotherapy (SRT) is developed as a new treatment option of lung metastasis in recent years. This study was to summarize the efficacy of SRT on lung metastasis.
A total of 39 patients with 62 lung metastatic lesions were treated by SRT in Cancer Center of Sun Yat-sen University. The median maximum diameter of the targets was 2.1 cm (1.2-4.9 cm), and the median maximum volume of the targets was 1.4 cm(3) (0.3-16.9 cm(3)). Of the 62 lesions, 21 were irradiated by single fraction with a dose of 20-24 Gy, and 41 were irradiated by 2-4 fractions with a dosage of 8-16 Gy/fraction and a total dose of 24-45 Gy. The median biologic effective dose (BED) of all lesions was 75 Gy (52.8-112.5 Gy).
Response rate was 83.3% at 3 months after treatment. For the lesions with maximum diameter of < or =3 cm, the response rates were 62.5% for BED<75 Gy and 93.5% for BED> or =75 Gy (P=0.023). Median survival time was 21.6 months (3.4-62.2 months). The 1-year and 2-year overall survival rates, local control survival rates and progression-free survival rates were 78.9% and 48.2%, 88.4% and 82.8%, 65.0% and 39.3%, respectively. The 2-year overall survival rate was significantly higher in the subgroup with single lung metastatic lesion than in the subgroup with multiple lung metastatic lesions (57.7% vs. 30.0%, P=0.047), and significantly higher in the subgroup without metastasis in other organs than in the subgroup with metastasis in other organs (54.9% vs. 28.6%, P=0.003). The occurrence of radiation pneumonitis (> or =grade 2) was 5.1% (2/39).
SRT is an effective and safe treatment for lung metastasis. The patients with single lung metastasis and without metastasis in other organs have better survival. BED> or =75 Gy has better local control effect on lung metastasis with maximum diameter of < or =3 cm.
肺转移瘤的传统治疗方法有限,治疗效果不尽人意。近年来,X线立体定向放射治疗(SRT)作为一种新的肺转移瘤治疗选择被研发出来。本研究旨在总结SRT治疗肺转移瘤的疗效。
中山大学肿瘤防治中心对39例患者共62个肺转移病灶进行了SRT治疗。靶区最大直径中位数为2.1 cm(1.2 - 4.9 cm),靶区最大体积中位数为1.4 cm³(0.3 - 16.9 cm³)。62个病灶中,21个采用单次分割照射,剂量为20 - 24 Gy,41个采用2 - 4次分割照射,剂量为8 - 16 Gy/次,总剂量为24 - 45 Gy。所有病灶的生物等效剂量(BED)中位数为75 Gy(52.8 - 112.5 Gy)。
治疗后3个月的缓解率为83.3%。对于最大直径≤3 cm的病灶,BED<75 Gy时缓解率为62.5%,BED≥75 Gy时缓解率为93.5%(P = 0.023)。中位生存时间为21.6个月(3.4 - 62.2个月)。1年和2年的总生存率、局部控制生存率和无进展生存率分别为78.9%和48.2%、88.4%和82.8%、65.0%和39.3%。单发性肺转移瘤亚组的2年总生存率显著高于多发性肺转移瘤亚组(57.7%对30.0%,P = 0.047),无其他器官转移亚组的2年总生存率显著高于有其他器官转移亚组(